Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inspection Fees For Drug, Ingredient Manufacturers Could End Up In PDUFA, Sen. Harkin Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The chairman of the HELP committee also open to a track and trace mechanism for drugs and their ingredients and denying U.S. entry to drugs from facilities that deny entry to U.S. inspectors.
Advertisement

Related Content

Inspection Fees Face Tough Road In Congress As PhRMA Remains Opposed
Supply Chain Security Issues To Emerge During Subcommittee Hearing On PDUFA
USP To Bring Global Perspective To Track And Trace Discussion
USP To Bring Global Perspective To Track And Trace Discussion
ANDA Complete Response Letters To Become Routine In 2012
ANDA Complete Response Letters To Become Routine In 2012
U.S. FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues
FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues
FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues
FDA Wants Authority To Enforce Track-And-Trace System For Drugs

Topics

Advertisement
UsernamePublicRestriction

Register

PS072767

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel